U.S. Medical Equipment Stock News

Appian (APPN) is back on investor radars after recent trading pressure, with the share price closing at US$28.62 and posting negative returns over the past week, month, past 3 months, year, and 5 years. See our latest analysis for Appian. The recent 7 day share price return of a 15.33% decline and 30 day share price return of a 22.31% decline, alongside a 1 year total shareholder return of a 12.74% decline and 5 year total shareholder return of an 86.03% decline, suggests momentum has been...

Recently, LexinFintech Holdings was featured in research on promising penny stocks, highlighting its strong financial health rating and position within China's consumer finance sector. An interesting angle from this coverage is that LexinFintech is being framed as a lower-priced entry point where fundamentals, rather than speculation, are the primary focus for investors. Against this backdrop of attention on LexinFintech’s financial strength, we’ll examine how this recognition may influence...

Updated guidance puts Xeris Biopharma Holdings (XERS) on investors’ radar Xeris Biopharma Holdings (XERS) lifted its full-year 2025 revenue outlook, now guiding to approximately US$292 million, above the prior US$285 million to US$290 million range. This is a shift that directly affects how investors may view the stock. See our latest analysis for Xeris Biopharma Holdings. The updated revenue outlook arrives after a mixed price run, with a 1-day share price return of 1.48% and a 90-day share...

Recent analyst moves around First BanCorp (FBP) are in focus after Piper Sandler initiated coverage with a Neutral rating, and the bank reported quarterly adjusted EPS above expectations but revenue below forecasts. See our latest analysis for First BanCorp. The recent analyst updates and earnings release sit against a share price that has eased slightly over the past month but still carries a 1-year total shareholder return of 11.93% and a 5-year total shareholder return of 149.60%. This...

Universal Technical Institute recently reported a 13.3% year-on-year revenue increase for the latest quarter, beating analyst expectations on revenue, EPS, and adjusted operating income, and lifted its full-year guidance. This combination of outperformance and guidance raise, the largest among its education services peers, highlights how management’s current outlook differs from earlier consensus assumptions. We’ll now examine how this stronger-than-expected quarter and raised full-year...

In recent days, analysts have taken diverging views on Chord Energy, with Citigroup and Pickering Energy Partners downgrading the stock while RBC Capital and Roth MKM reaffirmed positive ratings, against a backdrop of generally positive insider buying. This split in professional opinion, combined with directors adding to their holdings, highlights how shifting sentiment rather than new fundamentals is shaping investor debate around Chord Energy. We’ll now explore how this clash between...

Natera (NTRA) is back in focus after issuing guidance that points to a 39% year over year jump in Q4 revenue, projected 35% full year 2025 revenue growth, and fresh AI driven oncology updates. See our latest analysis for Natera. The past year has been eventful for Natera, with AI focused oncology partnerships, new clinical data readouts and expanded prenatal testing all coinciding with a 46.03% one year total shareholder return and a 22.61% 90 day share price return. This suggests momentum...

Winnebago Industries (WGO) is in focus after using the Florida RV SuperShow to showcase new RV lineups, including the Sunflyer Class C, Thrive lightweight trailer, and Grand Design RV’s Foundation 42GD destination trailer. See our latest analysis for Winnebago Industries. That product push comes as momentum in Winnebago Industries’ share price has been building, with a 56.64% 90 day share price return and a 9.28% 30 day share price return. However, the 5 year total shareholder return of...

If you are wondering whether Citigroup's current share price reflects its true worth, you are not alone. This article walks through how that value stacks up using several common valuation checks. Citigroup recently closed at US$118.04, with a 1 year return of 51.7%, a 3 year return of very large magnitude, a 5 year return of more than 7x, and shorter term moves of a 2.7% decline over 7 days, a 2.8% gain over 30 days, and a 0.6% decline year to date that may be catching investors'...

In January 2026, Polestar Automotive Holding UK PLC reported fourth-quarter 2025 retail sales of 15,608 cars and full-year sales of 60,119, both higher than the prior year. This step-up in retail volumes suggests that Polestar is managing to increase customer deliveries even as competition in the global EV market intensifies. We will now examine how this acceleration in full-year retail sales intersects with concerns about cash burn, competition, and Polestar’s longer-term investment...

Context for Globant’s recent share performance Globant (GLOB) has moved quietly on relatively mixed recent returns, combining a modest daily gain with weaker month performance and stronger past 3 months momentum, which puts its current valuation and fundamentals in sharper focus for investors. See our latest analysis for Globant. At around $68.20, Globant’s recent 1 day share price return of 1.07% sits against a weaker 30 day share price return of 1.84% and a stronger 90 day share price...

In mid-January 2026, The J.M. Smucker Co. announced its Board approved a US$1.10 per share quarterly dividend, payable on March 2, 2026, to shareholders of record as of February 13, reinforcing its ongoing capital return to investors. Around the same time, Morgan Stanley cut its rating on J.M. Smucker to Equal Weight, underscoring concerns about rising competitive pressures and valuation risks despite the steady dividend payout. With Morgan Stanley flagging increased competitive risk, we’ll...

Legend Biotech (LEGN) used its recent J.P. Morgan conference update to spotlight revenue growth, margin progress and an outlook for profitability in 2026, anchored by its multiple myeloma therapy CARVYKTI and partnership with Johnson & Johnson. See our latest analysis for Legend Biotech. Legend Biotech’s recent conference update comes after a tough run for investors, with a 90 day share price return of a 32.73% decline and a 1 year total shareholder return of a 32.21% decline, while the 30...

V2X (VVX) has been drawing fresh attention after securing a place on the Missile Defense Agency’s SHIELD IDIQ contract vehicle, a US$151.0b ceiling program tied to the Golden Dome American defense modernization effort. See our latest analysis for V2X. The SHIELD award and recent board appointments come at a time when momentum in V2X’s shares has picked up, with a 27.11% 1 month share price return and a 28.43% 1 year total shareholder return suggesting building interest around its defense...

Venture Global (VG) is back on investor radars after a recent price move, with the stock up 10.6% over the past day and 21.7% across the past week, outpacing its performance over the past month. See our latest analysis for Venture Global. The sharp 1 day share price return of 10.55% and 7 day share price return of 21.72% comes after a mixed few months, with a 30 day share price return of 38.58% contrasting with a 90 day share price decline of 5.27%. Recent momentum appears stronger when...

Minerals Technologies (MTX) has put its paper and packaging business in Asia firmly in focus, with three new satellite plants starting in 2025, a capacity doubling in India, and another plant planned in China for early 2026. See our latest analysis for Minerals Technologies. The expansion news comes as Minerals Technologies' share price has climbed 10.9% over the past month and 10.4% over the past quarter. However, the 1 year total shareholder return of an 11.2% decline and the low single...

BXP recently announced that Starr, a global investment and insurance organization, signed a 20-year lease for approximately 275,000 square feet, about 30% of the space, at 343 Madison Avenue, a 930,000 square foot, fully electric tower in Midtown Manhattan that BXP expects to deliver in late 2029. The long-term, headquarters lease with an investment-grade tenant at 343 Madison Avenue highlights early pre-leasing momentum and helps underpin BXP's large, sustainability-focused development,...

In December, Immunome, Inc. reported positive topline results from its Phase 3 RINGSIDE trial, showing Varegacestat improved progression-free survival versus placebo and plans to seek FDA approval in the second quarter of 2026. The data, including a marked reduction in the risk of death or disease progression and a high rate of tumor shrinkage, positions Varegacestat as a potentially important addition to Immunome’s oncology pipeline. Next, we’ll examine how Varegacestat’s strong Phase 3...

Fortrea Holdings (FTRE) saw its shares climb 4.8% after Evercore ISI upgraded the stock, citing stronger than expected revenue and profit margins, progress on debt reduction, and a quickening biopharma cycle. See our latest analysis for Fortrea Holdings. Even after the upgrade driven jump, Fortrea’s recent trading has been choppy. The 1 day share price return of 3.38% contrasts with 7 day and 30 day share price returns of 5.12% and 6.99% declines. A 90 day share price return of 58.35% hints...

What the recent return profile says about Post Holdings stock Post Holdings (POST) shares have tracked a mixed path recently, with a 1 day gain of about 1.3%, modest movement over the past week, and declines over the month and past 3 months. Over longer periods, the picture shifts, with negative total return over the past year but positive outcomes over 3 and 5 years. This can matter if you are thinking about holding the stock through different market cycles. Alongside that performance...

IDEAYA Biosciences (IDYA) is back in focus after a cluster of upbeat analyst reports highlighted its precision oncology pipeline and its partnerships with GlaxoSmithKline, Pfizer, and Gilead, drawing fresh attention to the stock. See our latest analysis for IDEAYA Biosciences. After a strong run that leaves the 1 year total shareholder return at 61.59% and the 3 year total shareholder return just over double, recent 7 day and 1 day share price weakness sits against a 90 day share price return...

Recently published government-funded research has challenged the scientific basis of existing US cannabis DUI laws, arguing they often penalize drivers without clear evidence of impairment and may be leading to wrongful incarceration. This push to modernize THC intoxication standards could ease regulatory frictions for the legal cannabis ecosystem, indirectly supporting ancillary players such as cannabis-focused landlord Innovative Industrial Properties. We’ll now consider how fresh scrutiny...

Prosperity Bancshares (PB) has been drawing attention after recent share price moves, with the stock closing at US$72.39 and showing mixed returns over the past year and the past 3 months. See our latest analysis for Prosperity Bancshares. The recent pullback in the 1-day share price return of 1% comes after a stronger 90-day share price return of 13.09%. At the same time, the 1-year total shareholder return shows a decline of 5.08%, indicating that longer term results have been more muted...

Asthma data and 2026 pipeline milestones come into focus Apogee Therapeutics (APGE) attracted fresh attention after reporting positive interim Phase 1b data for zumilokibart in mild to moderate asthma, alongside outlining key 2026 milestones across atopic dermatitis and other inflammatory indications. See our latest analysis for Apogee Therapeutics. Against this backdrop, Apogee’s recent asthma update and 2026 pipeline timeline arrive after a strong 90 day share price return of 41.85% and a 1...